119th Congress · introduced in the House · Jan 23, 2025
To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mifepristone, and for other purposes.
Official title from Congress.gov
Latest action (Jan 23, 2025): Referred to the House Committee on Energy and Commerce.
View on Congress.govPolicy area: Health
Congressional Research Service summary, version: Introduced in House (Jan 23, 2025)
This bill nullifies certain changes made by the Food and Drug Administration (FDA) to dispensing requirements for mifepristone. (Mifepristone is a drug that is approved to end pregnancies through 10 weeks gestation when used in conjunction with the drug misoprostol. The procedure is often referred to as medication abortion or the abortion pill.)
The FDA regulates the use of mifepristone through the Mifepristone Risk Evaluation and Mitigation Strategy (REMS) program. The program requires health care providers to comply with certain requirements in order to prescribe or dispense mifepristone to end a pregnancy; the program previously included an in-person dispensing requirement that required mifepristone to be directly dispensed to patients in clinics, medical offices, or hospitals. During the COVID-19 public health emergency, the FDA temporarily stopped enforcing the in-person dispensing requirement, which allowed mail-order pharmacies to fill and dispense mifepristone prescriptions.
In January 2023, the FDA modified program requirements so as to (1) remove the in-person dispensing requirement, and (2) require pharmacies to be certified in the program in order to dispense mifepristone. The modifications allow retail pharmacies, after receiving certification, to dispense mifepristone pursuant to prescriptions that are written by program-certified prescribers.
The bill nullifies the January 2023 changes and prohibits any similar changes in the future.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Introduced in House
Actions from Congress.gov, newest first.
Abortion · Drug safety, medical device, and laboratory regulation · Drug therapy · Prescription drugs
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 23, 2026.
23 citations.
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Family issues/Abortion/Adoption
$420,000
Spent on own lobbying
…3697, H.R.685 - SAVE Moms and Babies Act of 2026; Patient Protection and Affordable Care Act; Abortion funding; IVF issues; National Defense Authorization Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Health Issues
$420,000
Spent on own lobbying
…3697, H.R.685 - SAVE Moms and Babies Act of 2026; Patient Protection and Affordable Care Act; Abortion funding; IVF issues; National Defense Authorization Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Medical/Disease Research/Clinical Labs
$420,000
Spent on own lobbying
…3697, H.R.685 - SAVE Moms and Babies Act of 2026; Patient Protection and Affordable Care Act; Abortion funding; IVF issues; National Defense Authorization Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Pharmacy
$420,000
Spent on own lobbying
Shield Laws Chemical abortion drugs S. 1631, H. R. 5646 - Restoring Safeguards for Dangerous Abortion Drugs Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 21, 2026 · issue area: Law Enforcement/Crime/Criminal Justice
$420,000
Spent on own lobbying
S.2955, H.R.6466 - Forced Abortion Prevention and Accountability Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Family issues/Abortion/Adoption
$380,000
Spent on own lobbying
…issues; National Defense Authorization Act; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Health Issues
$380,000
Spent on own lobbying
…Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2025 Patient Protection and Affordable Care Act National Defense Authorization Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Pharmacy
$380,000
Spent on own lobbying
Shield Laws Chemical abortion drugs S. 1631, H. R. 5646 - Restoring Safeguards for Dangerous Abortion Drugs Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Law Enforcement/Crime/Criminal Justice
$380,000
Spent on own lobbying
S.2955, H.R.6466 - Forced Abortion Prevention and Accountability Act H.R. 679 - To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mi…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Health Issues
$420,000
Spent on own lobbying
…the Gridlock Act; Patient Protection and Affordable Care Act; Contraception Issues; National Defense Authorization Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Family issues/Abortion/Adoption
$420,000
Spent on own lobbying
…Authorization Act; Supreme Court Decisions; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Pharmacy
$420,000
Spent on own lobbying
…t Life Act of 2025; Supreme Court Decisions; S. 1631, H. R. 5646 Restoring Safeguards for Dangerous Abortion Drugs Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Law Enforcement/Crime/Criminal Justice
$420,000
Spent on own lobbying
S.2955 , H.R.6466 Forced Abortion Prevention and Accountability Act; H.R. 629 Ending Chemical Abortions Act; H.R. 679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Family issues/Abortion/Adoption
$360,000
Spent on own lobbying
…026; S. 5371 Continuing Appropriations and Extensions Act, 2026; Contraception issues; IVF issues; National Defense Authorization Act; Supreme Court Decisions; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Health Issues
$360,000
Spent on own lobbying
…for informing the general public, and for other purposes; Patient Protection and Affordable Care Act; Contraception Issues; National Defense Authorization Act; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Pharmacy
$360,000
Spent on own lobbying
Shield Laws; Chemical abortion drugs; Supreme Court Decisions; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Family issues/Abortion/Adoption
$490,000
Spent on own lobbying
…382 Family First Act; National Defense Authorization Act; H.R.271 Defund Planned Parenthood Act; S. 203 Defund Planned Parenthood Act; Supreme Court Decisions; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Health Issues
$490,000
Spent on own lobbying
…Abortion Ban Act; S.178, H.R.627 Ensuring Accurate and Complete Abortion Data Reporting Act of 2025; Contraception Issues; National Defense Authorization Act; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Pharmacy
$490,000
Spent on own lobbying
Shield Laws; H.R. 685 Support and Value Expectant Moms and Babies Act; Chemical abortion drugs; Supreme Court Decisions; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
HERITAGE ACTION FOR AMERICA · lobbying firm or registrant: HERITAGE ACTION FOR AMERICA
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 22, 2025 · issue area: Health Issues
$100,000
Spent on own lobbying
…re Freedom Act," all provisions. HR 629 "Ending Chemical Abortions Act of 2023," all provisions. HR632 "Protecting Life on College Campus Act," all provisions. HR679 "To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mif…
Congress inferred from the report year; bill number matches Congress.gov records and the bill predates the report; no title was cited with it. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 17, 2025 · issue area: Pharmacy
$600,000
Spent on own lobbying
Shield laws; H.R. 685 Support and Value Expectant Moms and Babies Act; Chemical abortion drugs; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 17, 2025 · issue area: Family issues/Abortion/Adoption
$600,000
Spent on own lobbying
…e for Moms Act; Pregnancy is Not an Illness Act; S.205/H.R.2251 Protecting Individuals with Down Syndrome Act; S.250 Protecting Life in Foreign Assistance Act; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
SUSAN B ANTHONY LIST · lobbying firm or registrant: SUSAN B ANTHONY LIST
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 17, 2025 · issue area: Health Issues
$600,000
Spent on own lobbying
…ata Reporting Act of 2025; H.R. 570 To amend the Internal Revenue Code of 1986 to allow the child tax credit with respect to stillbirths; Contraception Issues; H.R.679 To nullify the modifications made by the Food and Drug Administration in January 2023 to the risk evaluation and mitigation strategy for the abortion pill mife…
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing